Neuropeptide AF (93-110), Human

Neuropeptide AF (93-110), Human is a synthetic peptide fragment corresponding to amino acid residues 93 to 110 of the human neuropeptide AF precursor. As a member of the RFamide peptide family, this compound is characterized by its C-terminal Arg-Phe-NH₂ motif, which is implicated in diverse neuromodulatory processes. Neuropeptide AF and its derivatives are of significant interest in neurobiology due to their involvement in modulating neuronal excitability, synaptic transmission, and various physiological responses. The availability of this defined peptide fragment enables researchers to dissect the structure-function relationships of RFamide peptides and explore their mechanisms of action in both central and peripheral nervous systems.

Neuropeptide signaling studies: Researchers utilize Neuropeptide AF (93-110), Human in experimental systems to investigate RFamide receptor activation and downstream signaling pathways. By applying this peptide to cultured neurons or brain slice preparations, it is possible to delineate the specific receptors and second messenger cascades involved in neuropeptide-mediated modulation of neuronal activity. Such studies provide valuable insights into the molecular basis of neuropeptide signaling and help clarify the functional repertoire of RFamide peptides in mammalian neural circuits.

Electrophysiological research: The peptide fragment serves as a powerful tool for probing the effects of RFamide peptides on neuronal membrane properties and synaptic function. Through patch-clamp recordings or extracellular field potential measurements, scientists can assess changes in neuronal excitability, ion channel activity, or synaptic plasticity following application of the compound. These experiments contribute to a deeper understanding of the physiological roles and pharmacological profiles of endogenous neuropeptides in the human nervous system.

Peptide-receptor interaction assays: Neuropeptide AF (93-110), Human is frequently employed in receptor binding studies, including radioligand displacement assays and fluorescence-based binding analyses. These approaches enable quantification of binding affinities, receptor selectivity, and kinetic parameters, facilitating the characterization of novel RFamide receptors or the screening of potential modulators. Such data are essential for mapping peptide-receptor networks and for the rational design of receptor-targeted research tools.

Peptide synthesis and analog development: The defined sequence of this peptide fragment makes it a valuable reference standard in solid-phase peptide synthesis and analytical method development. Synthetic chemists and peptide engineers use it as a template to generate analogs with modified sequences, enhanced stability, or altered receptor affinities. These analogs can be systematically evaluated for structure-activity relationships, paving the way for the identification of new modulatory peptides or peptide-based research probes.

Functional studies in neuroendocrine systems: The compound is also employed in studies examining the influence of RFamide peptides on neuroendocrine regulation. By applying the peptide to pituitary or hypothalamic tissue preparations, researchers can assess its effects on hormone secretion, signal transduction, and neuroendocrine feedback mechanisms. These investigations are instrumental in clarifying how neuropeptides integrate neural and endocrine functions, and how they contribute to physiological homeostasis in mammalian systems.

1. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line

2. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications

3. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

4. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

5. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging